曲美他嗪治疗冠心病心力衰竭的疗效分析

目的 观察曲美他嗪治疗冠心病（CHD）心力衰竭（CHF）的临床疗效,为CHF的临床治疗提供更多的理论依据.方法 收集我院2011年6月-2012年4月心血管内科收治疗的CHD伴发CHF的患者72例,患者随机分为常规治疗（A,n=36）组和曲美他嗪治疗（B,n=36）组.观察治疗后左心室射血分数（LVEF）、6 min步行试验的变化.对照两组的临床疗效.结果 A组和B组治疗前左心室射血分数（LVEF）和6min步行最大距离无显著性差异（P＞0.05）,治疗后A组和B组中上述指标得到了显著的改善（P＜0.05或P＜0.01）,但B组的改善显著优于A组（P＜0.05）.A和B组的临床治疗有效率分别为52.8％和75.0％,B组疗效显著优于A组（P＜0.05）.结论 曲美他嗪治疗CHF临床疗效显著,值得推广应用.

Clininal analysis of Qumei trimetazidine treatment of Coronary heart disease and heart failur

Objective To observe Qumei trimetazidine treatment of coronary heart disease （CHD） heart failure （CHF） clinical effi- cacy, provide more theoretical basis for clinical treatment of CHF. Methods in our hospital from 2011 June to 2012 April cardio- vascular department of internal medicine receiving treatment in 72 CHD patients with CHF, patients were randomly divided into conventional treatment （A, n=36） Qumei trimetazidine treatment group （group B, n=36）. Left ventricular ejection fraction were ob- served after treatment （LVEF）, 6 minutes walk test changes. The control effect of two groups. Results in A group and B group be- fore the treatment of left ventricular ejection fraction （LVEF） and 6 minutes walk from the maximum distance had no significant difference （P＆gt; 0.0~）, after treatment, the indexes of A and B groups were significantly improved （P＆lt; 0.05 or P＆lt; 0.01）, but the B group improved significantly better than the group A （P＆lt; 0.05）. The clinical treatment of A and B group were 52.8% and 75%, the effect of B group was higher than that of A group （P＆lt; 0.05）. Conclusion Qumei trimetazidine treatment of CHF clini- cal curative effect~ it is worthy of popularization and application.